OncoMatch/Clinical Trials/NCT06563505
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Is NCT06563505 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mosunetuzumab and Zanubrutinib for lymphoma.
Treatment: Mosunetuzumab · Zanubrutinib — To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20 monoclonal antibody
Have received at least 1 prior treatment including CD20 monoclonal antibody
Cannot have received: chemotherapeutic agent or other anti-lymphoma agent (investigational or otherwise)
Treatment with any chemotherapeutic agent, or treatment with any other anti-lymphoma agent (investigational or otherwise) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to first investigational agent administration.
Lab requirements
Blood counts
Blood counts below if without lymphoma cause for cytopenia: Hemoglobin ≥ 8 g/dL; Platelets ≥ 75 x 10^9/L; ANC ≥ 1.0x10^9/L. If cytopenia due to lymphoma: Hemoglobin ≥ 6 g/dL (no transfusion within 7 days prior to treatment); Platelets ≥ 50 x 10^9/L; ANC ≥ 0.5x10^9/L
Kidney function
Creatinine clearance ≥ 40 ml/min calculated by modified Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 institutional ULN, unless consistent with Gilbert's (ratio between total and direct bilirubin > 5); AST (SGOT) and ALT (SGPT) ≤ 3 x institutional ULN; Alkaline phosphatase < 2.5 ULN
Patients must have adequate organ and marrow function as defined below: * Total bilirubin ≤ 1.5 institutional ULN, unless consistent with Gilbert's (ratio between total and direct bilirubin > 5) * AST (SGOT) and ALT (SGPT) ≤ 3 x institutional ULN * Alkaline phosphatase < 2.5 ULN * Creatinine clearance ≥ 40 ml/min calculated by modified Cockcroft-Gault formula * Blood counts below if without lymphoma cause for cytopenia * Hemoglobin ≥ 8 g/dL * Platelets ≥ 75 x 10^9/L * Absolute neutrophil count (ANC) ≥ 1.0x10^9/L * Blood counts below if cytopenia are due to lymphoma (such as bone marrow involvement or splenomegaly) * Hemoglobin ≥ 6 g/dL (no transfusion within 7 days prior to treatment) * Platelets ≥ 50 x 10^9/L * Absolute neutrophil count (ANC) ≥ 0.5x10^9/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify